Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 April 2025 | Story Tshepo Tsotetsi | Photo Supplied
Prof Tameshnie Deane
Prof Tameshnie Deane has been appointed an Acting Judge of the Free State High Court during the Faculty of Law’s milestone 80th anniversary.

Prof Tameshnie Deane, Vice-Dean: Research, Postgraduate Studies and Internationalisation in the Faculty of Law at the University of the Free State (UFS), has been appointed as an Acting Judge of the Free State High Court. Her appointment, which runs from 14 April to 30 May 2025, marks a significant moment for the faculty, and for the university’s broader academic and judicial community.

This is not Prof Deane’s first judicial appointment. Since 2019, she has served as an Acting Judge in various High Court divisions across South Africa, an experience that has shaped her legal thinking and affirmed her position as a respected voice in both academia and the courtroom.

“This appointment is an extraordinary milestone, both personally and professionally,” she said. “These appointments signify the recognition of my expertise and contributions to the legal field and academia over the years. Serving as an Acting Judge is a profound honour that reflects the trust placed in my ability to uphold justice, engage critically with complex legal matters, and contribute meaningfully to society.”

 

Bridging theory and the bench

Prof Deane is deeply committed to the idea that legal education and legal practice are not separate paths, but two sides of the same coin. Her work as a judge, she believes, enhances her ability to shape future legal minds, while her academic background brings fresh perspective to the courtroom.

“Serving as an Acting Judge offers invaluable insights into the practical application of legal principles, enriching my research and enabling me to mentor postgraduate students with a stronger emphasis on the real-world implications of their studies,” she said.

“Additionally, this experience deepens my understanding of comparative legal systems, which aligns perfectly with my focus on fostering internationalisation. On a broader professional level, it strengthens my ability to drive impactful scholarship and innovation, while advancing the university’s mission of academic excellence and global engagement.”

She added: “My dual grounding in academia and the legal profession equips me with a multidimensional perspective. From academia, I bring a deep commitment to critical thinking, analytical rigour, and intellectual curiosity, which can enhance the depth and breadth of judicial reasoning. From the legal field, I offer pragmatic insights and an unwavering dedication to justice.”

 

Institutional pride in a milestone year

The timing of the appointment is also significant. As the UFS Faculty of Law celebrates its 80th anniversary this year, Prof Deane’s appointment offers a moment to reflect on the faculty’s role in producing legal professionals who not only understand the law but actively shape its application.

“This moment highlights the enduring legacy of excellence, leadership, and innovation that the faculty has cultivated over 80 years,” she said. “It sends a powerful message to students and young academics: that dedication, perseverance, and a commitment to both intellectual and ethical standards can pave the way to significant achievements.”

Prof Serges Kamga, Dean of the Faculty of Law, echoed this sentiment, saying of Prof Deane’s appointment: “It illustrates our faculty’s commitment to producing legal professionals who actively influence and strengthen judicial practices. It bridges academic scholarship with judicial application, demonstrating our faculty’s dedication to shaping South Africa’s legal landscape and enhancing its national and international reputation.”

 

A message to young legal minds

Prof Deane believes the appointment sends a powerful message, especially to students and early-career academics. “Preparation for such a role requires a meticulous approach – both professionally and personally,” she said. “Professionally, it involves staying current with legal developments, understanding procedural rules, and immersing oneself in the dynamics of the court and the types of cases that may arise.”

“Personally, it demands resilience, adaptability, and a steadfast commitment to justice. However, sometimes opportunities like this are also shaped by a bit of luck – being in the right place at the right time, or meeting the right people who recognise your potential. Such moments serve as a reminder to remain open to possibilities and to always put one’s best foot forward, as you never know what doors may open.”

When asked about the types of cases she hopes to preside over, Prof Deane said her focus is on approaching every matter with diligence and fairness.

“As cases are assigned to us, my focus is not on selecting specific legal issues, but rather on approaching every matter with the utmost diligence and impartiality,” she said. “Each case, regardless of its nature, carries the potential to contribute to the development of law and have a significant impact on the lives of those involved. My aim is to engage deeply with every case, ensuring that decisions are both fair and informed, while appreciating the broader implications they may have for legal precedent and societal progress.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept